JAMA Study Blood Test for Alzheimer’s
Recent studies have demonstrated significant advancements in the early detection of Alzheimer’s disease using blood-based biomarkers, particularly the phosphorylated tau 217 (p-tau217) protein. Research published in JAMA Neurology highlights that these blood tests offer diagnostic accuracy comparable to traditional methods like cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) scans, achieving accuracy rates around 80-92%(
JAMA Network
)(
UCL
). This makes them a promising tool for early intervention, particularly as they are less invasive and more cost-effective than lumbar punctures and imaging. However, the generalizability of these tests across diverse populations remains a challenge, necessitating further research to ensure their efficacy across different demographic groups(
Neurology live
).